SlideShare a Scribd company logo
1 of 8
Rare disease vs Tropical
Disease
Lessons for Tropical Disease drug development
1. Tax Credits – 50% tax credit for clinical research and testing
expenses
2. Waiver of User Fees
3. 7 years of marketing exclusivity upon FDA approval of a
specific orphan drug for a specific indication.
Incentives associated with Rare disease
designation:
Orphan Drug Approval
Trends
Taken from www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/UCM581335.pdf
FDA Breakthrough Therapy Approvals
Taken from www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/UCM581335.pdf
● Review time
approximately
3 months faster
● Development
time 2.2 years
less
For drugs to treat a serious condition where preliminary clinical evidence indicates that
the drug may demonstrate a substantial improvement
Rare Disease and FDA’s Priority Review
Designation
Taken from www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/UCM581335.pdf
Tropical Disease and FDA’s Priority Review
Designation
● If a sponsor achieves approval of a new drug application (NDA), the sponsor
receives a “Priority review voucher”.
● PRV for tropical disease from FDA is around 2 Million USD.
● Designated indications include Malaria, Cholera, TB, Ebola and Zika.
Issues with Tropical Disease Drug development
● High prevalence of the targeted disease but low average income of target market.
● Weak infrastructure for distribution
● Lack of an effective system of intellectual property protection.
● Lack of adequate diagnosis.
Recommendations for Tropical Disease Drug
development
● Partnership with International research funds (eg. WHO and NGOs) for Access.
● Partner with Academia to drive down R&D costs.
● Advance purchase commitments
○ Patent exclusivity
○ Tech transfer
○ Preferential Pricing
● International pharmaceutical policies need to be developed by the United states.
● Transferable patent exclusivity eg. Gilead- Sovaldi-India.
● Sell Drugs and kits for easy diagnosis together.

More Related Content

What's hot

Presentation: A journey to better medicine labels - an update on TGO 92
Presentation: A journey to better medicine labels - an update on TGO 92Presentation: A journey to better medicine labels - an update on TGO 92
Presentation: A journey to better medicine labels - an update on TGO 92TGA Australia
 
Presentation: Improving the regulation of generic medicines in Australia
Presentation: Improving the regulation of generic medicines in AustraliaPresentation: Improving the regulation of generic medicines in Australia
Presentation: Improving the regulation of generic medicines in AustraliaTGA Australia
 
Presentation: Spotlight on complementary medicines MMDR reforms
Presentation: Spotlight on complementary medicines MMDR reformsPresentation: Spotlight on complementary medicines MMDR reforms
Presentation: Spotlight on complementary medicines MMDR reformsTGA Australia
 
CLSA-BCG-Report-Tracking-FDA-Drug-Review-Performance-March-2016-Final2
CLSA-BCG-Report-Tracking-FDA-Drug-Review-Performance-March-2016-Final2CLSA-BCG-Report-Tracking-FDA-Drug-Review-Performance-March-2016-Final2
CLSA-BCG-Report-Tracking-FDA-Drug-Review-Performance-March-2016-Final2Will Zasadny
 
Protocol prohibited medications in clinical trials
Protocol prohibited medications in clinical trialsProtocol prohibited medications in clinical trials
Protocol prohibited medications in clinical trialsDr.Rajeswari Gopinathan
 
Presentation: Prescription Medicines Reforms
Presentation: Prescription Medicines ReformsPresentation: Prescription Medicines Reforms
Presentation: Prescription Medicines ReformsTGA Australia
 
Understanding the Drug Development Process
Understanding the Drug Development ProcessUnderstanding the Drug Development Process
Understanding the Drug Development ProcessEMMAIntl
 
Presentation: Medicinal Cannabis - what's happening?
Presentation: Medicinal Cannabis - what's happening?Presentation: Medicinal Cannabis - what's happening?
Presentation: Medicinal Cannabis - what's happening?TGA Australia
 
Risk management plan (RMP) requirements: When and why is an RMP required
Risk management plan (RMP) requirements: When and why is an RMP requiredRisk management plan (RMP) requirements: When and why is an RMP required
Risk management plan (RMP) requirements: When and why is an RMP requiredTGA Australia
 
Topra Combination Products Gert Bos
Topra Combination Products Gert BosTopra Combination Products Gert Bos
Topra Combination Products Gert BosGertwbos
 
Overview of the Complementary Medicines regulatory framework
Overview of the Complementary Medicines regulatory frameworkOverview of the Complementary Medicines regulatory framework
Overview of the Complementary Medicines regulatory frameworkTGA Australia
 
Annexure 1 pharmacovigilance
Annexure 1  pharmacovigilanceAnnexure 1  pharmacovigilance
Annexure 1 pharmacovigilancedrxray
 
Presentation: Advertising therapeutic goods to consumers
Presentation: Advertising therapeutic goods to consumers Presentation: Advertising therapeutic goods to consumers
Presentation: Advertising therapeutic goods to consumers TGA Australia
 
Pharmacovigilance (gpv p) training in india
Pharmacovigilance (gpv p) training in india Pharmacovigilance (gpv p) training in india
Pharmacovigilance (gpv p) training in india Radhika Nagare
 
Pharmacovigilance full information
Pharmacovigilance full informationPharmacovigilance full information
Pharmacovigilance full informationRavindra Kumar
 
Consultation on “Guidance on variations to biologicals included in the Register”
Consultation on “Guidance on variations to biologicals included in the Register”Consultation on “Guidance on variations to biologicals included in the Register”
Consultation on “Guidance on variations to biologicals included in the Register”TGA Australia
 
Impact of innovative therapies on regulation of therapeutic goods - John Sker...
Impact of innovative therapies on regulation of therapeutic goods - John Sker...Impact of innovative therapies on regulation of therapeutic goods - John Sker...
Impact of innovative therapies on regulation of therapeutic goods - John Sker...TGA Australia
 
TGA presentation: Provisional approval pathway for prescription medicines
TGA presentation: Provisional approval pathway for prescription medicinesTGA presentation: Provisional approval pathway for prescription medicines
TGA presentation: Provisional approval pathway for prescription medicinesTGA Australia
 

What's hot (19)

Presentation: A journey to better medicine labels - an update on TGO 92
Presentation: A journey to better medicine labels - an update on TGO 92Presentation: A journey to better medicine labels - an update on TGO 92
Presentation: A journey to better medicine labels - an update on TGO 92
 
Presentation: Improving the regulation of generic medicines in Australia
Presentation: Improving the regulation of generic medicines in AustraliaPresentation: Improving the regulation of generic medicines in Australia
Presentation: Improving the regulation of generic medicines in Australia
 
Presentation: Spotlight on complementary medicines MMDR reforms
Presentation: Spotlight on complementary medicines MMDR reformsPresentation: Spotlight on complementary medicines MMDR reforms
Presentation: Spotlight on complementary medicines MMDR reforms
 
CLSA-BCG-Report-Tracking-FDA-Drug-Review-Performance-March-2016-Final2
CLSA-BCG-Report-Tracking-FDA-Drug-Review-Performance-March-2016-Final2CLSA-BCG-Report-Tracking-FDA-Drug-Review-Performance-March-2016-Final2
CLSA-BCG-Report-Tracking-FDA-Drug-Review-Performance-March-2016-Final2
 
Protocol prohibited medications in clinical trials
Protocol prohibited medications in clinical trialsProtocol prohibited medications in clinical trials
Protocol prohibited medications in clinical trials
 
Presentation: Prescription Medicines Reforms
Presentation: Prescription Medicines ReformsPresentation: Prescription Medicines Reforms
Presentation: Prescription Medicines Reforms
 
Understanding the Drug Development Process
Understanding the Drug Development ProcessUnderstanding the Drug Development Process
Understanding the Drug Development Process
 
Pharmacovigilance and adr
Pharmacovigilance and adrPharmacovigilance and adr
Pharmacovigilance and adr
 
Presentation: Medicinal Cannabis - what's happening?
Presentation: Medicinal Cannabis - what's happening?Presentation: Medicinal Cannabis - what's happening?
Presentation: Medicinal Cannabis - what's happening?
 
Risk management plan (RMP) requirements: When and why is an RMP required
Risk management plan (RMP) requirements: When and why is an RMP requiredRisk management plan (RMP) requirements: When and why is an RMP required
Risk management plan (RMP) requirements: When and why is an RMP required
 
Topra Combination Products Gert Bos
Topra Combination Products Gert BosTopra Combination Products Gert Bos
Topra Combination Products Gert Bos
 
Overview of the Complementary Medicines regulatory framework
Overview of the Complementary Medicines regulatory frameworkOverview of the Complementary Medicines regulatory framework
Overview of the Complementary Medicines regulatory framework
 
Annexure 1 pharmacovigilance
Annexure 1  pharmacovigilanceAnnexure 1  pharmacovigilance
Annexure 1 pharmacovigilance
 
Presentation: Advertising therapeutic goods to consumers
Presentation: Advertising therapeutic goods to consumers Presentation: Advertising therapeutic goods to consumers
Presentation: Advertising therapeutic goods to consumers
 
Pharmacovigilance (gpv p) training in india
Pharmacovigilance (gpv p) training in india Pharmacovigilance (gpv p) training in india
Pharmacovigilance (gpv p) training in india
 
Pharmacovigilance full information
Pharmacovigilance full informationPharmacovigilance full information
Pharmacovigilance full information
 
Consultation on “Guidance on variations to biologicals included in the Register”
Consultation on “Guidance on variations to biologicals included in the Register”Consultation on “Guidance on variations to biologicals included in the Register”
Consultation on “Guidance on variations to biologicals included in the Register”
 
Impact of innovative therapies on regulation of therapeutic goods - John Sker...
Impact of innovative therapies on regulation of therapeutic goods - John Sker...Impact of innovative therapies on regulation of therapeutic goods - John Sker...
Impact of innovative therapies on regulation of therapeutic goods - John Sker...
 
TGA presentation: Provisional approval pathway for prescription medicines
TGA presentation: Provisional approval pathway for prescription medicinesTGA presentation: Provisional approval pathway for prescription medicines
TGA presentation: Provisional approval pathway for prescription medicines
 

Similar to Lessons for Tropical Disease drug development

Clinical Trials & Drug Approval Process
Clinical Trials & Drug Approval ProcessClinical Trials & Drug Approval Process
Clinical Trials & Drug Approval ProcessKumaraguru Veerasamy
 
RegulatoryIssues In Drug management cycle
RegulatoryIssues In Drug management cycleRegulatoryIssues In Drug management cycle
RegulatoryIssues In Drug management cycleHarunMohamed7
 
Module 2 Final June 2007
Module 2 Final June 2007Module 2 Final June 2007
Module 2 Final June 2007Flavio Guzmán
 
Fast track drugs - Rapid study and Approval
Fast track drugs - Rapid study and ApprovalFast track drugs - Rapid study and Approval
Fast track drugs - Rapid study and ApprovalDebashish Sarkar
 
FDA drug approval and review process
FDA drug approval and review processFDA drug approval and review process
FDA drug approval and review processNIGAR FATIMA
 
USFDA-Fast Track Designation
USFDA-Fast Track DesignationUSFDA-Fast Track Designation
USFDA-Fast Track Designationvansh raina
 
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfGLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfLokeshThakre6
 
Fast track drugs- Rapid study and Approval
Fast track drugs- Rapid study and ApprovalFast track drugs- Rapid study and Approval
Fast track drugs- Rapid study and ApprovalDebashish Sarkar
 
INDA- Investigation New Drug Application
INDA- Investigation New Drug ApplicationINDA- Investigation New Drug Application
INDA- Investigation New Drug ApplicationDr. Jigar Vyas
 
Breakthrough Therapy Designation- Spring 2014 Reg. Intelligence
Breakthrough Therapy Designation- Spring 2014 Reg. IntelligenceBreakthrough Therapy Designation- Spring 2014 Reg. Intelligence
Breakthrough Therapy Designation- Spring 2014 Reg. IntelligenceCharles Kemmerer
 
FDA Drug Approval Regulations & Safety
FDA Drug Approval Regulations & SafetyFDA Drug Approval Regulations & Safety
FDA Drug Approval Regulations & SafetyDr Dev Kambhampati
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)Manish Rajput
 
Principles of Drug Discovery and Development
Principles of Drug Discovery and DevelopmentPrinciples of Drug Discovery and Development
Principles of Drug Discovery and DevelopmentMANIKANDAN V
 
Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history EstelaJeffery653
 
Phases 3,4 and 5 of clinical trials
Phases 3,4 and 5 of  clinical trialsPhases 3,4 and 5 of  clinical trials
Phases 3,4 and 5 of clinical trialsDrShrey Bhatia
 

Similar to Lessons for Tropical Disease drug development (20)

Accelerated clinical trials
Accelerated clinical trialsAccelerated clinical trials
Accelerated clinical trials
 
Clinical Trials & Drug Approval Process
Clinical Trials & Drug Approval ProcessClinical Trials & Drug Approval Process
Clinical Trials & Drug Approval Process
 
RegulatoryIssues In Drug management cycle
RegulatoryIssues In Drug management cycleRegulatoryIssues In Drug management cycle
RegulatoryIssues In Drug management cycle
 
Unit2 clinical trials
Unit2 clinical trialsUnit2 clinical trials
Unit2 clinical trials
 
Module 2 Final June 2007
Module 2 Final June 2007Module 2 Final June 2007
Module 2 Final June 2007
 
Ind by pankaj
Ind by pankajInd by pankaj
Ind by pankaj
 
Fast track drugs - Rapid study and Approval
Fast track drugs - Rapid study and ApprovalFast track drugs - Rapid study and Approval
Fast track drugs - Rapid study and Approval
 
FDA drug approval and review process
FDA drug approval and review processFDA drug approval and review process
FDA drug approval and review process
 
USFDA-Fast Track Designation
USFDA-Fast Track DesignationUSFDA-Fast Track Designation
USFDA-Fast Track Designation
 
Ucm358301
Ucm358301Ucm358301
Ucm358301
 
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfGLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdf
 
Fast track drugs- Rapid study and Approval
Fast track drugs- Rapid study and ApprovalFast track drugs- Rapid study and Approval
Fast track drugs- Rapid study and Approval
 
INDA- Investigation New Drug Application
INDA- Investigation New Drug ApplicationINDA- Investigation New Drug Application
INDA- Investigation New Drug Application
 
Breakthrough Therapy Designation- Spring 2014 Reg. Intelligence
Breakthrough Therapy Designation- Spring 2014 Reg. IntelligenceBreakthrough Therapy Designation- Spring 2014 Reg. Intelligence
Breakthrough Therapy Designation- Spring 2014 Reg. Intelligence
 
Overview of FDA requirements for IND
Overview of FDA requirements for INDOverview of FDA requirements for IND
Overview of FDA requirements for IND
 
FDA Drug Approval Regulations & Safety
FDA Drug Approval Regulations & SafetyFDA Drug Approval Regulations & Safety
FDA Drug Approval Regulations & Safety
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
 
Principles of Drug Discovery and Development
Principles of Drug Discovery and DevelopmentPrinciples of Drug Discovery and Development
Principles of Drug Discovery and Development
 
Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history
 
Phases 3,4 and 5 of clinical trials
Phases 3,4 and 5 of  clinical trialsPhases 3,4 and 5 of  clinical trials
Phases 3,4 and 5 of clinical trials
 

Recently uploaded

The Art of Decision-Making: Navigating Complexity and Uncertainty
The Art of Decision-Making: Navigating Complexity and UncertaintyThe Art of Decision-Making: Navigating Complexity and Uncertainty
The Art of Decision-Making: Navigating Complexity and Uncertaintycapivisgroup
 
JAJPUR CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JAJPUR ESCORTS SERVICE PROVIDE
JAJPUR CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JAJPUR  ESCORTS SERVICE PROVIDEJAJPUR CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JAJPUR  ESCORTS SERVICE PROVIDE
JAJPUR CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JAJPUR ESCORTS SERVICE PROVIDEkajalroy875762
 
A DAY IN THE LIFE OF A SALESPERSON .pptx
A DAY IN THE LIFE OF A SALESPERSON .pptxA DAY IN THE LIFE OF A SALESPERSON .pptx
A DAY IN THE LIFE OF A SALESPERSON .pptxseemajojo02
 
The Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdf
The Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdfThe Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdf
The Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdfbelieveminhh
 
Pre Engineered Building Manufacturers Hyderabad.pptx
Pre Engineered  Building Manufacturers Hyderabad.pptxPre Engineered  Building Manufacturers Hyderabad.pptx
Pre Engineered Building Manufacturers Hyderabad.pptxRoofing Contractor
 
Moradia Isolada com Logradouro; Detached house with patio in Penacova
Moradia Isolada com Logradouro; Detached house with patio in PenacovaMoradia Isolada com Logradouro; Detached house with patio in Penacova
Moradia Isolada com Logradouro; Detached house with patio in Penacovaimostorept
 
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptxQSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptxDitasDelaCruz
 
GURGAON CALL GIRL ❤ 8272964427❤ CALL GIRLS IN GURGAON ESCORTS SERVICE PROVIDE
GURGAON CALL GIRL ❤ 8272964427❤ CALL GIRLS IN GURGAON  ESCORTS SERVICE PROVIDEGURGAON CALL GIRL ❤ 8272964427❤ CALL GIRLS IN GURGAON  ESCORTS SERVICE PROVIDE
GURGAON CALL GIRL ❤ 8272964427❤ CALL GIRLS IN GURGAON ESCORTS SERVICE PROVIDEkajalroy875762
 
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAIGetting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAITim Wilson
 
Thompson_Taylor_MBBS_PB1_2024-03 (1)- Project & Portfolio 2.pptx
Thompson_Taylor_MBBS_PB1_2024-03 (1)- Project & Portfolio 2.pptxThompson_Taylor_MBBS_PB1_2024-03 (1)- Project & Portfolio 2.pptx
Thompson_Taylor_MBBS_PB1_2024-03 (1)- Project & Portfolio 2.pptxtmthompson1
 
JIND CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JIND ESCORTS SERVICE PROVIDE
JIND CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JIND ESCORTS SERVICE PROVIDEJIND CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JIND ESCORTS SERVICE PROVIDE
JIND CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JIND ESCORTS SERVICE PROVIDEkajalroy875762
 
Ital Liptz - all about Itai Liptz. news.
Ital Liptz - all about Itai Liptz. news.Ital Liptz - all about Itai Liptz. news.
Ital Liptz - all about Itai Liptz. news.htj82vpw
 
Putting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxPutting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxCynthia Clay
 
Falcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon investment
 
Understanding Financial Accounting 3rd Canadian Edition by Christopher D. Bur...
Understanding Financial Accounting 3rd Canadian Edition by Christopher D. Bur...Understanding Financial Accounting 3rd Canadian Edition by Christopher D. Bur...
Understanding Financial Accounting 3rd Canadian Edition by Christopher D. Bur...ssuserf63bd7
 
Challenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
Challenges and Opportunities: A Qualitative Study on Tax Compliance in PakistanChallenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
Challenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistanvineshkumarsajnani12
 
Jual obat aborsi Hongkong ( 085657271886 ) Cytote pil telat bulan penggugur k...
Jual obat aborsi Hongkong ( 085657271886 ) Cytote pil telat bulan penggugur k...Jual obat aborsi Hongkong ( 085657271886 ) Cytote pil telat bulan penggugur k...
Jual obat aborsi Hongkong ( 085657271886 ) Cytote pil telat bulan penggugur k...Klinik kandungan
 

Recently uploaded (20)

The Art of Decision-Making: Navigating Complexity and Uncertainty
The Art of Decision-Making: Navigating Complexity and UncertaintyThe Art of Decision-Making: Navigating Complexity and Uncertainty
The Art of Decision-Making: Navigating Complexity and Uncertainty
 
JAJPUR CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JAJPUR ESCORTS SERVICE PROVIDE
JAJPUR CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JAJPUR  ESCORTS SERVICE PROVIDEJAJPUR CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JAJPUR  ESCORTS SERVICE PROVIDE
JAJPUR CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JAJPUR ESCORTS SERVICE PROVIDE
 
A DAY IN THE LIFE OF A SALESPERSON .pptx
A DAY IN THE LIFE OF A SALESPERSON .pptxA DAY IN THE LIFE OF A SALESPERSON .pptx
A DAY IN THE LIFE OF A SALESPERSON .pptx
 
The Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdf
The Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdfThe Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdf
The Vietnam Believer Newsletter_May 13th, 2024_ENVol. 007.pdf
 
Pre Engineered Building Manufacturers Hyderabad.pptx
Pre Engineered  Building Manufacturers Hyderabad.pptxPre Engineered  Building Manufacturers Hyderabad.pptx
Pre Engineered Building Manufacturers Hyderabad.pptx
 
Moradia Isolada com Logradouro; Detached house with patio in Penacova
Moradia Isolada com Logradouro; Detached house with patio in PenacovaMoradia Isolada com Logradouro; Detached house with patio in Penacova
Moradia Isolada com Logradouro; Detached house with patio in Penacova
 
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptxQSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
QSM Chap 10 Service Culture in Tourism and Hospitality Industry.pptx
 
WheelTug Short Pitch Deck 2024 | Byond Insights
WheelTug Short Pitch Deck 2024 | Byond InsightsWheelTug Short Pitch Deck 2024 | Byond Insights
WheelTug Short Pitch Deck 2024 | Byond Insights
 
GURGAON CALL GIRL ❤ 8272964427❤ CALL GIRLS IN GURGAON ESCORTS SERVICE PROVIDE
GURGAON CALL GIRL ❤ 8272964427❤ CALL GIRLS IN GURGAON  ESCORTS SERVICE PROVIDEGURGAON CALL GIRL ❤ 8272964427❤ CALL GIRLS IN GURGAON  ESCORTS SERVICE PROVIDE
GURGAON CALL GIRL ❤ 8272964427❤ CALL GIRLS IN GURGAON ESCORTS SERVICE PROVIDE
 
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAIGetting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
 
Thompson_Taylor_MBBS_PB1_2024-03 (1)- Project & Portfolio 2.pptx
Thompson_Taylor_MBBS_PB1_2024-03 (1)- Project & Portfolio 2.pptxThompson_Taylor_MBBS_PB1_2024-03 (1)- Project & Portfolio 2.pptx
Thompson_Taylor_MBBS_PB1_2024-03 (1)- Project & Portfolio 2.pptx
 
JIND CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JIND ESCORTS SERVICE PROVIDE
JIND CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JIND ESCORTS SERVICE PROVIDEJIND CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JIND ESCORTS SERVICE PROVIDE
JIND CALL GIRL ❤ 8272964427❤ CALL GIRLS IN JIND ESCORTS SERVICE PROVIDE
 
Ital Liptz - all about Itai Liptz. news.
Ital Liptz - all about Itai Liptz. news.Ital Liptz - all about Itai Liptz. news.
Ital Liptz - all about Itai Liptz. news.
 
HomeRoots Pitch Deck | Investor Insights | April 2024
HomeRoots Pitch Deck | Investor Insights | April 2024HomeRoots Pitch Deck | Investor Insights | April 2024
HomeRoots Pitch Deck | Investor Insights | April 2024
 
Putting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxPutting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptx
 
Falcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business Potential
 
Understanding Financial Accounting 3rd Canadian Edition by Christopher D. Bur...
Understanding Financial Accounting 3rd Canadian Edition by Christopher D. Bur...Understanding Financial Accounting 3rd Canadian Edition by Christopher D. Bur...
Understanding Financial Accounting 3rd Canadian Edition by Christopher D. Bur...
 
Contact +971581248768 for 100% original and safe abortion pills available for...
Contact +971581248768 for 100% original and safe abortion pills available for...Contact +971581248768 for 100% original and safe abortion pills available for...
Contact +971581248768 for 100% original and safe abortion pills available for...
 
Challenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
Challenges and Opportunities: A Qualitative Study on Tax Compliance in PakistanChallenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
Challenges and Opportunities: A Qualitative Study on Tax Compliance in Pakistan
 
Jual obat aborsi Hongkong ( 085657271886 ) Cytote pil telat bulan penggugur k...
Jual obat aborsi Hongkong ( 085657271886 ) Cytote pil telat bulan penggugur k...Jual obat aborsi Hongkong ( 085657271886 ) Cytote pil telat bulan penggugur k...
Jual obat aborsi Hongkong ( 085657271886 ) Cytote pil telat bulan penggugur k...
 

Lessons for Tropical Disease drug development

  • 1. Rare disease vs Tropical Disease Lessons for Tropical Disease drug development
  • 2. 1. Tax Credits – 50% tax credit for clinical research and testing expenses 2. Waiver of User Fees 3. 7 years of marketing exclusivity upon FDA approval of a specific orphan drug for a specific indication. Incentives associated with Rare disease designation:
  • 3. Orphan Drug Approval Trends Taken from www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/UCM581335.pdf
  • 4. FDA Breakthrough Therapy Approvals Taken from www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/UCM581335.pdf ● Review time approximately 3 months faster ● Development time 2.2 years less For drugs to treat a serious condition where preliminary clinical evidence indicates that the drug may demonstrate a substantial improvement
  • 5. Rare Disease and FDA’s Priority Review Designation Taken from www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/UCM581335.pdf
  • 6. Tropical Disease and FDA’s Priority Review Designation ● If a sponsor achieves approval of a new drug application (NDA), the sponsor receives a “Priority review voucher”. ● PRV for tropical disease from FDA is around 2 Million USD. ● Designated indications include Malaria, Cholera, TB, Ebola and Zika.
  • 7. Issues with Tropical Disease Drug development ● High prevalence of the targeted disease but low average income of target market. ● Weak infrastructure for distribution ● Lack of an effective system of intellectual property protection. ● Lack of adequate diagnosis.
  • 8. Recommendations for Tropical Disease Drug development ● Partnership with International research funds (eg. WHO and NGOs) for Access. ● Partner with Academia to drive down R&D costs. ● Advance purchase commitments ○ Patent exclusivity ○ Tech transfer ○ Preferential Pricing ● International pharmaceutical policies need to be developed by the United states. ● Transferable patent exclusivity eg. Gilead- Sovaldi-India. ● Sell Drugs and kits for easy diagnosis together.